NERV Financials Minerva Neurosciences, Inc.
12 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | — | -$293M | — | — | — | — | $82M |
| 2024 | $0 | $1M | — | — | — | — | $21M |
| 2023 | $0 | -$30M | — | — | — | — | $41M |
| 2022 | $0 | -$32M | — | — | -$25M | — | $36M |
| 2021 | $0 | -$50M | — | — | — | — | $61M |
| 2020 | $0 | $2M | — | — | — | — | $25M |
| 2019 | $0 | -$72M | — | — | — | — | $21M |
| 2018 | $0 | -$50M | — | — | — | — | $50M |
| 2017 | — | -$32M | — | — | $3M | — | $26M |
| 2016 | — | -$31M | — | — | — | — | $83M |
| 2015 | — | -$27M | — | — | — | — | $14M |
| 2014 | — | -$57M | — | — | — | — | $19M |
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | — | -$125M | — | — | — | — | $33M |
| Dec '25 | — | -$284M | — | — | — | — | $82M |
| Sep '25 | — | -$3M | — | — | — | — | $12M |
| Jun '25 | — | -$3M | — | — | — | — | $15M |
| Mar '25 | — | -$4M | — | — | — | — | $17M |
| Dec '24 | — | -$4M | — | — | — | — | $21M |
| Sep '24 | — | $23M | — | — | — | — | $27M |
| Jun '24 | — | -$8M | — | — | — | — | $31M |
| Mar '24 | — | -$9M | — | — | — | — | $35M |
| Dec '23 | — | -$9M | — | — | — | — | $41M |
| Sep '23 | — | -$8M | — | — | — | — | $47M |
| Jun '23 | — | -$6M | — | — | — | — | $52M |
| Mar '23 | — | -$7M | — | — | — | — | $36M |
| Dec '22 | — | -$7M | — | — | — | — | $36M |
| Sep '22 | — | -$7M | — | — | — | — | $40M |
| Jun '22 | — | -$9M | — | — | — | — | $50M |
| Mar '22 | — | -$10M | — | — | — | — | $55M |
| Dec '21 | $0 | -$21M | — | — | — | — | $61M |
| Sep '21 | $0 | -$9M | — | — | — | — | $66M |
| Jun '21 | $0 | -$11M | — | — | — | — | $74M |
Valuation over time
How the market has priced NERV against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has risen from 70.9× (Dec '24) to 124.3× (Nov '25).
Frequently asked questions
Is NERV growing its revenue and profit?
See the revenue and net-income charts above for Minerva Neurosciences, Inc.'s multi-year trend.
How much debt does NERV have?
As of FY2025, Minerva Neurosciences, Inc. reported — of total debt against $82M of cash.
What is NERV's profit margin?
In FY2025, gross margin was —, operating margin —, and net margin —.
What is NERV's P/E ratio?
As of Jun '26, Minerva Neurosciences, Inc. traded at a price-to-earnings ratio of about 124.3× (market cap ÷ latest annual net income). The valuation charts above show how its P/E have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.